文献速递瓣膜外科

Avalus牛心包生物瓣主动脉瓣置换七年多中心前瞻性结果

Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

该前瞻性非随机多中心研究纳入1132例外科主动脉瓣置换患者,评估Avalus带支架牛心包生物瓣的7年结局。7年免于结构性瓣膜衰败(SVD)或需再干预的严重血流动力学障碍的Kaplan-Meier率为1.2%(0.5-2.5%),无SVD裁定病例,生存率82.6%。结论认为该瓣膜7年耐久性良好,临床结局与血流动力学表现稳定。

要点

  • 7年免于SVD或需再干预严重血流动力学障碍的KM率为1.2%(0.5-2.5%),无SVD裁定病例。
  • 7年生存率82.6%(79.5-85.0%),再干预KM事件率5.7%(4.3-7.7%)。
  • 平均主动脉瓣跨瓣压差13.8±5.9 mmHg,有效瓣口面积1.99±0.53 cm²。

核心结论

  • Avalus瓣膜在7年随访中显示出优异的耐久性,临床结局良好且血流动力学表现稳定。

研究设计与样本

  • 前瞻性非随机多中心试验,全球39个中心纳入1132例有外科主动脉瓣置换指征的患者。
  • 平均年龄70岁,男性854例(75%),平均STS死亡风险2.0±1.4%,NYHA I/II级659例(58%),合并至少一项同期手术577例(51%)。
  • 主要终点为7年随访时因结构性瓣膜衰败(SVD)免于外科取出或经导管瓣中瓣再干预,采用Kaplan-Meier分析。

主要发现

  • 7年免于SVD或需再干预的严重血流动力学障碍的KM率为1.2%(0.5-2.5%),无SVD裁定病例。
  • 7年生存率82.6%(79.5-85.0%)。
  • 7年KM事件率:再干预5.7%(4.3-7.7%),心内膜炎6.3%(4.9-8.3%),瓣膜血栓0.4%(0.1-1.1%)。
  • 平均主动脉瓣跨瓣压差13.8±5.9 mmHg,无量纲速度指数0.42±0.09,有效瓣口面积1.99±0.53 cm²。

临床怎么用

  • 对于有外科主动脉瓣置换指征的患者,Avalus带支架牛心包生物瓣可作为7年耐久性良好的选择之一。

局限性

  • 本研究为前瞻性非随机试验,未设随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Safety, efficacy and durability are important considerations when selecting a bioprosthesis for aortic valve replacement (AVR). This study assessed 7-year clinical outcomes and haemodynamic performance of the Avalus bioprosthesis. METHODS: Patients indicated for surgical AVR were enrolled in this prospective, nonrandomized trial, conducted across 39 sites globally. The primary end-point of this analysis was freedom from surgical explant or percutaneous valve-in-valve reintervention due to structural valve deterioration (SVD) at 7 years of follow-up, determined using Kaplan-Meier (KM) analysis. We also evaluated a composite end-point of SVD and/or severe haemodynamic dysfunction requiring reintervention. Survival, valve-related safety events and haemodynamic performance were assessed. Deaths and safety events were adjudicated by an independent clinical events committee. RESULTS: A total of 1132 patients underwent surgical AVR. Mean age was 70 years; 854 patients (75%) were men. The mean STS risk of mortality was 2.0 ± 1.4%, and 659 patients (58%) had a New York Heart Association classification of I/II. One or more concomitant procedures were performed in 577 patients (51%). At 7 years, the Kaplan-Meier rate of freedom from SVD/severe haemodynamic dysfunction requiring reintervention was 1.2% (0.5-2.5%) with no cases adjudicated as SVD. The survival rate was 82.6% (79.5-85.0%). The KM event rate was 5.7% (4.3-7.7%) for reintervention, 6.3% (4.9-8.3%) for endocarditis and 0.4% (0.1-1.1%) for valve thrombosis. Mean aortic gradient, dimensionless velocity index and effective orifice area were 13.8 ± 5.9 mmHg, 0.42 ± 0.09 and 1.99 ± 0.53 cm2, respectively. CONCLUSIONS: This analysis demonstrated excellent durability of the Avalus valve with good clinical outcomes and stable haemodynamic performance through 7 years of follow-up.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Sabik JF, Rao V, Dagenais F, et al. Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis. Eur J Cardiothorac Surg. 2024. PMID: 39565905. doi:10.1093/ejcts/ezae414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。